GLP-1 Medications and Testosterone: What the Research Shows
Can Ozempic, Wegovy, and Mounjaro raise low testosterone in men? Here's what trials and meta-analyses show about GLP-1 drugs, weight loss, and male hormones.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on July 9, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
For millions of men carrying extra weight, low testosterone and obesity travel together — and each one feeds the other. As GLP-1 medications like Ozempic, Wegovy, and Mounjaro reshape obesity treatment, a practical question keeps surfacing in urology and endocrinology clinics: can these drugs lift low testosterone back into a normal range? The link between GLP-1 medications and testosterone is now backed by a growing stack of trials, and the early answer is encouraging, though the mechanism is more about the pounds lost than the drug itself.
The scale of the problem is easy to underestimate. In the largest study of its kind, roughly 40% of obese men — and half of obese men who also have type 2 diabetes — had subnormal free testosterone, almost always with the inappropriately normal gonadotropin pattern that defines functional (or "metabolic") hypogonadism.
Evidence: "Free testosterone concentrations were subnormal in 40% of obese nondiabetic men and in 50% of obese men with type 2 diabetes, with inappropriately normal luteinizing hormone concentrations indicating hypogonadotropic hypogonadism." — Dhindsa S, et al. Diabetes Care. 2018;41(7):1516–1525. DOI: 10.2337/dc17-2510
That "inappropriately normal" detail matters. In these men the testes usually work fine — the brain simply stops sending a strong enough signal because excess fat tissue disrupts the hormonal loop. Fix the metabolic problem, and the signal often recovers. This is exactly why weight loss, and now GLP-1 medications, sit at the center of the conversation about restoring male hormones.
Why Obesity Lowers Testosterone
Understanding whether GLP-1 drugs help requires knowing why fat tissue drives testosterone down in the first place. The problem is not one broken gland but a self-reinforcing loop.
Fat tissue is metabolically active. It contains the enzyme aromatase, which converts testosterone into estradiol. The more fat a man carries, the more of his testosterone gets siphoned into estrogen, and that rising estradiol signals the brain to dial back luteinizing hormone (LH) — the messenger that tells the testes to make testosterone. Chronic inflammation and insulin resistance, both hallmarks of obesity and metabolic syndrome, suppress the same hypothalamic signal. The result is lower testosterone, which in turn makes it easier to gain fat and lose muscle, tightening the loop.
Because the machinery is intact and only the signal is suppressed, this kind of hypogonadism is often reversible. The decisive evidence comes from weight-loss studies that predate GLP-1 drugs entirely.
Evidence: "Weight loss, obtained by either low-calorie diet or bariatric surgery, is associated with a significant increase in total and free testosterone as well as in gonadotropins, with the degree of body weight loss being the best predictor of testosterone rise." — Corona G, et al. European Journal of Endocrinology. 2013;168(6):829–843. DOI: 10.1530/EJE-12-0955
This meta-analysis is the foundation for everything that follows. It established a dose-response relationship: the more weight a man loses, the more his testosterone climbs. And because GLP-1 medications produce some of the largest sustained weight losses ever seen outside surgery, they became obvious candidates for reversing metabolic hypogonadism.
What GLP-1 Medications Do to Testosterone
The strongest overview to date pooled the available trials of GLP-1 receptor agonists and testicular function. The direction of effect is clear and consistent.
Evidence: "GLP-1 receptor agonist treatment produced a significant increase in total serum testosterone, with parallel increases in free testosterone, sex hormone-binding globulin, and gonadotropins, alongside reductions in body weight, BMI, and HbA1c." — Salvio G, et al. Andrology. 2025;13(8):2022–2034. DOI: 10.1111/andr.70022
Across seven studies and 680 men, GLP-1 therapy raised total and free testosterone while also nudging LH and FSH upward — the signature of the brain's signal switching back on. Just as important is what the same authors were careful to say it does not prove: that GLP-1 drugs act directly on the testes. They concluded the current literature "does not allow us to demonstrate a direct action" on testicular tissue, pointing instead to weight loss and improved metabolic health as the engine. In other words, GLP-1 medications appear to raise testosterone the same way diet and surgery do — by removing the metabolic burden that was suppressing it — just more reliably and with less effort from the patient.
The tirzepatide pilot study
The most head-turning data come from a controlled trial that pitted tirzepatide (the GLP-1/GIP drug sold as Mounjaro and Zepbound) directly against standard testosterone therapy.
Evidence: "After two months, men treated with tirzepatide showed significantly greater reductions in body weight, waist circumference, and fat mass, and greater improvements in lean mass and erectile function, than men on lifestyle intervention alone, with endogenous testosterone production increasing." — Cannarella R, et al. Reproductive Biology and Endocrinology. 2025;23(1):92. DOI: 10.1186/s12958-025-01425-9
In this study of 83 obese men with metabolic hypogonadism, tirzepatide did something testosterone gel cannot: it raised the body's own testosterone production rather than replacing it from outside. That distinction has real consequences, which the next section spells out.
Endogenous Testosterone vs. Replacement Therapy
For decades the default fix for a low reading was testosterone replacement therapy (TRT) — gels, injections, or pellets that supply the hormone directly. TRT works quickly and predictably, but it carries a well-known trade-off: giving the body external testosterone tells the brain to shut down its own production, which shrinks the testes and impairs fertility and sperm production.
GLP-1 medications work in the opposite direction. By reducing fat mass, they lift the suppression on the hypothalamus, so the testes make more testosterone on their own. The distinction is not academic:
| Feature | Testosterone replacement (TRT) | GLP-1 medication |
|---|---|---|
| Source of testosterone | External (gel, injection) | Body's own production |
| Effect on sperm/fertility | Usually suppresses | Preserves or improves |
| Effect on body weight | Modest fat loss | Substantial weight loss |
| Testicular size | Can shrink | Preserved |
| Treats root cause | No (masks it) | Yes (reduces fat burden) |
For a younger man who wants to preserve fertility, or any man who would rather fix the underlying metabolic problem than manage a lifelong prescription, that difference is the whole point. And the fertility angle is more than theoretical.
Evidence: "Semaglutide treatment over 24 weeks was associated with a significant improvement in the proportion of morphologically normal spermatozoa in obese men with type 2 diabetes and functional hypogonadism." — Gregorič N, et al. Diabetes, Obesity and Metabolism. 2025. DOI: 10.1111/dom.16042
Improved sperm morphology alongside rising testosterone is precisely the pattern you would expect from reversing the metabolic cause rather than papering over it with external hormone. Still, this is early evidence from small trials, not a green light to prescribe GLP-1 drugs as a fertility treatment.
What This Means in Practice
The research supports a straightforward, if cautious, takeaway: in men whose low testosterone stems from obesity, meaningful weight loss on a GLP-1 medication can raise testosterone into a healthier range without the fertility cost of TRT. Several caveats keep this honest.
It is weight loss doing the work. The benefit tracks the pounds lost, so the men who lose the most see the biggest hormonal gains — and a man who takes the drug but loses little weight should not expect much testosterone change. Pairing the medication with resistance training to protect muscle mass makes the body-composition improvement, and likely the hormonal one, more durable.
It does not fix primary hypogonadism. If the testes themselves are damaged — from injury, chemotherapy, genetic causes, or aging-related decline unrelated to weight — a GLP-1 drug will not restore testosterone, because the problem is not a suppressed signal. These men still need evaluation by an endocrinologist or urologist, and often TRT.
The trials are still small and short. Most run two to six months in a few dozen men. They show a consistent direction of effect, but not yet the long-term, large-scale confirmation that would let doctors prescribe GLP-1 drugs specifically to treat low testosterone. For now, rising testosterone is best understood as a welcome bonus of treating obesity, not a standalone indication.
Get tested before assuming. Symptoms like low libido, fatigue, and poor erections overlap with many conditions. A proper diagnosis needs a morning blood test — ideally repeated — plus LH and FSH to distinguish the functional, weight-related pattern (which GLP-1 drugs can help) from primary testicular failure (which they cannot).
Key Takeaways
Low testosterone and obesity are two sides of the same metabolic coin, and GLP-1 medications are proving to be a compelling way to break the cycle. By driving substantial weight loss, drugs like semaglutide and tirzepatide lift the fat-driven suppression of the male hormone axis, raising the body's own testosterone production — a fundamentally different and more physiological approach than replacing the hormone from outside.
The evidence is consistent but still maturing: testosterone rises, gonadotropins recover, and early data even hint at better sperm quality, all apparently downstream of weight loss rather than a direct drug effect. Men with obesity-related low testosterone stand to gain the most, especially those hoping to protect fertility. Anyone considering this path should confirm the diagnosis with proper testing and treat any hormonal improvement as one more reason weight loss matters — not as a shortcut around it.
References
- Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic Hypogonadism in Men With Diabesity. Diabetes Care. 2018;41(7):1516–1525. DOI: 10.2337/dc17-2510
- Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology. 2013;168(6):829–843. DOI: 10.1530/EJE-12-0955
- Salvio G, Ciarloni A, Ambo N, et al. Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis. Andrology. 2025;13(8):2022–2034. DOI: 10.1111/andr.70022
- Cannarella R, La Vignera S, Condorelli RA, et al. Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study. Reproductive Biology and Endocrinology. 2025;23(1):92. DOI: 10.1186/s12958-025-01425-9
- Gregorič N, Šmigoc Schweiger D, Battelino T, et al. Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes, Obesity and Metabolism. 2025. DOI: 10.1111/dom.16042
Last updated: 2026-07-09 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.